WebMay 4, 2024 · “It’s been a highly active early 2024 for Karyopharm, marked most notably by establishment of a planned approval path for selinexor in relapsed or refractory diffuse large B-cell lymphoma ... WebJul 16, 2024 · Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of < 6 months. The SADAL study evaluated single-agent oral selinexor in patients with RR DLBCL and demonstrated an overall response rate (ORR) of 29.1% with median duration of response (DOR) of 9.3 months.
AACR 2024 Preview and Top Data Readouts Key Insights
WebApr 12, 2024 · TP-1287 was designed as an investigational oral phosphate prodrug of alvocidib, a CDK9 inhibitor. Alvocidib is able to bind at the ATP binding site of CDK9, which interrupts CDK9’s phosphorylation. This reduces messenger RNA in certain genes such as c-MYC and MCL-1. By downregulating c-MYC and MCL-1, it may be possible to achieve … WebNov 5, 2024 · The FDA has granted a fast track designation to the first-in-class, oral SETD2 inhibitor, EZM0414, for use as a potential therapeutic option in adult patients with … capitol kassel heute
Novel treatments in B cell non-Hodgkin’s lymphomas The BMJ
http://mdedge.ma1.medscape.com/podcasts/blood-cancer/fda-approvals-hematology-and-oncology-part-ii-new-oral-formulations-ret-and WebMar 13, 2024 · Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have limited treatment options, particularly if they are transplantation or chimeric antigen receptor (CAR) T-cell ineligible, and novel therapeutics are needed. ... An 86-year-old woman with relapsed DLBCL received a novel, first-in-class small molecule inhibitor of N ... WebDec 17, 2024 · Selinexor is a novel first-in-class oral selective inhibitor of nuclear export, that has meaningful activity in heavily pre-treated r/r DLBCL and other hematological and solid malignancies. Single agent Selinexor demonstrates an ORR of 28%, PFS of 3.6 months and OS of 9.1 months in the pivotal phase 2b SADAL study. capitol jeep san jose